Walter K. Nahm

Apr 2, 2024 | onlinelibrary.wiley.com | Emma Guttman-Yassky |Kenji Kabashima |Delphine Staumont-Sallé |Walter K. Nahm

Specific inhibition of interleukin (IL)-13 with tralokinumab reduced cutaneous type 2 inflammation and improved epidermal pathology in adult patients with moderate-to-severe atopic dermatitis (AD). Tralokinumab reduced AD-associated serum biomarkers, including CC-motif chemokine ligand 17, periostin, immunoglobulin E, and IL-22.